Related Funds
Fund Name | Location |
Automagi | Japan, Tokyo |
Benefit China Asset Management | Beijing, Beijing, China |
Coface | Bois-colombes, France, Ile-de-France |
E-Synergy | California, Los Angeles, United States |
Envy Capital | Farmington Hills, Michigan, United States |
Federal-Mogul Motorparts | - |
FengHe Fund Management | China, Guangdong Province, Huangpu District |
frontierCities | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
Gradiente Sgr | Italy, Padua, Veneto |
Innovent | California, United States, Walnut Creek |
Meridian Asset Management | Salt Lake City, United States, Utah |
Morningside Capital | Chicago, Illinois, United States |
OneEleven | Canada, Ontario, Toronto |
Pangmao VC | China, Shanghai |
Reliance Industries | India, Maharashtra, Mumbai |
Rhodes Partners | Bethesda, Maryland, United States |
Sathguru Catalyzer Advisors | Andhra Pradesh, Hyderabad, India |
Shanghai Quanli Touzi | China, Shanghai |
Solactive | Frankfurt, Germany, Hessen |
Upscale | England, London, United Kingdom |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Raisecare | $15M | 03 Nov 2023 | Qingdao Shi, Shandong, China | ||
Aikeda Bio | 01 Sep 2023 | China, China | |||
Jyss Bio | 25 Jul 2021 | Hangzhou, Zhejiang, China | |||
Simcere Pharma | $92M | 04 Jun 2021 | Xuanwu District, Jiangsu, China | ||
YiChao YiLiao | 01 Feb 2021 | Shanghai, China | |||
Raynovent | $43M | 15 Dec 2020 | Guangzhou, Guangdong, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Raisecare | $15M | 03 Nov 2023 | Qingdao Shi, Shandong, China | ||
Aikeda Bio | 01 Sep 2023 | China, China | |||
Jyss Bio | 25 Jul 2021 | Hangzhou, Zhejiang, China | |||
Simcere Pharma | $92M | 04 Jun 2021 | Xuanwu District, Jiangsu, China | ||
YiChao YiLiao | 01 Feb 2021 | Shanghai, China | |||
Raynovent | $43M | 15 Dec 2020 | Guangzhou, Guangdong, China |